Leanne Dyal

Hamilton, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A hybrid automated event adjudication system for clinical trials.

A hybrid automated event adjudication system for clinical trials.

Journal: Clinical trials (London, England)

Published: February 03, 2023

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.

Journal: Circulation

Published: January 05, 2022

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Journal: The New England journal of medicine

Published: July 02, 2021

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

Journal: European journal of preventive cardiology

Published: June 04, 2021

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Journal: Heart (British Cardiac Society)

Published: December 07, 2020

Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.

Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.

Journal: Journal of the American College of Cardiology

Published: October 19, 2020

Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.

Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.

Journal: JAMA cardiology

Published: September 30, 2020

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.

Journal: Cardiovascular diabetology

Published: September 30, 2020

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.

Journal: Stroke

Published: September 21, 2020

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.

Journal: European heart journal

Published: June 01, 2020

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.

Journal: The lancet. Diabetes & endocrinology

Published: November 18, 2019

Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.

Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.

Journal: JAMA neurology

Published: September 17, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026